Close

Maravai LifeSciences (MRVI) Tops Q4 EPS by 2c, Revenues Beat; Offers FY21 EPS/Revenue Guidance Above Consensus

Go back to Maravai LifeSciences (MRVI) Tops Q4 EPS by 2c, Revenues Beat; Offers FY21 EPS/Revenue Guidance Above Consensus

Maravai LifeScience Holdings Inc. (MRVI) PT Raised to $34 at Credit Suisse

March 1, 2021 6:10 AM EST

Credit Suisse analyst Erin Wilson Wright raised the price target on Maravai LifeScience Holdings Inc. (NASDAQ: MRVI) to $34.00 (from $31.00) while maintaining a Outperform rating.... More